With many gene therapies in development for an increasing number of indications, their curative promise presents a unique competitive dynamic as they enter the market over the coming years. A one-time treatment with the potential to cure patients could create a “winner takes all” dynamic, whereby second and later entrants for the same indication would have significantly smaller patient populations, such as treatment-resistant or inappropriate patient segments.
Approaching the final frontier: Are we in a golden decade of drug development for the central nervous system?
In this CRA Insights, the authors Will Foster, Kees Chamberlain, Joanne Clark, and Carl Lottig recount the recent scientific and technological advances in...